Long COVID Doesn ’ t Always Look Like You Think It Does
In the spring of 2023, after her third case of COVID-19, Jennifer Robertson started to feel strange. Her heart raced all day long and she could barely sleep at night. She had dizzy spells. She felt pins and needles in her arm, she says, a “buzzing feeling” in her foot, and pain in her legs and lymph nodes. She broke out in a rash. She smelled “phantom” cigarette smoke, even when none was in the air.
[time-brightcove not-tgx=”true”]
Robertson, 48, had a feeling COVID-19 might have somehow been the trigger. She knew about Long COVID, the name for chronic symptoms following an infection...
Source: TIME: Health - February 27, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Gilead to snap up liver disease biotech CymaBay for $4.3B
Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease drug candidate. The California big biotech will pay cash to buy CymaBay Therapeutics, the companies said Monday morning. The deal is for…#gilead #fda #expected #cymabay #seladelpar #pbc #unlock (Source: Reuters: Health)
Source: Reuters: Health - February 12, 2024 Category: Consumer Health News Source Type: news
Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases
Kyverna Therapeutics started its first day as a public biotech on a strong note, with its shares $KYTX rising more than 50% Thursday afternoon after pricing at $22 and raising $319 million for the company. But don’t call the Nasdaq IPO an overnight success. It took five years to…#kyverna #kyvernavillage #gilead #aseriesbextension #unlock (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2024 Category: Consumer Health News Source Type: news
Kyverna ’s $319M IPO adds to fervor for autoimmune cell therapies
California biotech Kyverna Therapeutics will garner $319 million from its Thursday morning Nasdaq debut as it rides a small but welcome wave of investor enthusiasm for initial public offerings. The mid-stage cell therapy maker priced at $22 apiece, selling 14.5 million…#kyverna #unlock (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2024 Category: Consumer Health News Source Type: news
How do you tell when a politician is lying? The tics, tells and tricks to watch for
Perceptions of dishonesty can end careers – but Australia’s leaders are ‘pretty good at dancing around the actual questions’Get ourmorning and afternoon news emails,free app ordaily news podcastThey may exaggerate, evade or embellish the truth. They may bloviate, or bluster or blame their memory. But, experts say, smart politicians rarely outright lie.“People tell each other lies,” the former cabinet minister Christopher Pyne said this week at the start of theABC documentary Nemesis. The first of a three-part series, it covered Australia ’s Abbott-Turnbull-Morrison years between 2013 and 2022.Sign up for Guar...
Source: Guardian Unlimited Science - February 1, 2024 Category: Science Authors: Tory Shepherd Tags: Australian politics Australia news Tony Abbott Anthony Albanese Scott Morrison Malcolm Turnbull John Howard Coalition Bob Katter Labor party Psychology Source Type: news
The effect of nabiximols on driving ability in adults with chronic tic disorders: results of a substudy analysis of the double-blind, randomized, placebo-controlled CANNA-TICS trial - M üller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A.
BACKGROUND: The multicenter, randomized, double-blind, parallel-group, phase IIIb CANNA-TICS (CANNAbinoids in the treatment of TICS) trial showed clear trends for improvement of tics, depression, and quality of life with nabiximols versus placebo in adult ... (Source: SafetyLit)
Source: SafetyLit - January 26, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Mild traumatic brain injury as a risk factor for Parkinsonism, tics, and akathisia: a systematic review and meta-analysis - Khan N, Romila L, Ciobica A, Burlui V, Kamal FZ, Mavroudis I.
This meta-analysis aimed to assess the association between mild traumatic brain injury (mTBI) and the risk of developing Parkinsonism. A systematic literature review was conducted using PubMed, Embase, and Cochrane Library databases. Studies were eligible ... (Source: SafetyLit)
Source: SafetyLit - January 26, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Promising New Therapies for Managing Tourette Syndrome Promising New Therapies for Managing Tourette Syndrome
Home-administered, wrist-worn median nerve stimulation is among new treatment avenues being pursued to manage tics in patients with Tourette syndrome.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - October 27, 2023 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
FDA advisors unanimously reject Intarcia's embattled type 2 diabetes treatment
I2o Therapeutics CEO Kurt Graves set out on Thursday to make a case to a panel of the FDA’s expert advisors that the benefits of his company’s twice-rejected implant to treat type 2 diabetes outweigh its risks — but the committee wasn’t convinced. The FDA’s Endocrinologic…#kurtgraves #fda #2diabetes #metabolic #unlock (Source: Reuters: Health)
Source: Reuters: Health - September 22, 2023 Category: Consumer Health News Source Type: news
Machine-Learning Tool Sorts Tics From Non-Tics on Video Machine-Learning Tool Sorts Tics From Non-Tics on Video
The time-consuming task of differentiating tics from non-tic movements on videos of people with suspected tic disorders could soon be streamlined with a machine-learning tool, German scientists say.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - September 1, 2023 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Machine learning algorithm applied in classifying tic from non-tic movements
Machine learning is a promising tool for detecting and distinguishing tics from extra movements, according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark. COPENHAGEN, Denmark, Aug. 27, 2023 /PRNewswire-PRWeb/... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 27, 2023 Category: Pharmaceuticals Tags: SVY Source Type: news
How to tell if you've REALLY got Tourette's as Mel Sykes self-diagnoses disorder that affects Lewis Capaldi and Billie Eilish: Doctors say you CAN suddenly get tics in your 50s... but the true cause might be something else
The 52-year-old TV presenter's announcement has shone a spotlight on the poorly-understood tic disorder. Tourette's is thought to affect around 300,000 Brits. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2023 Category: Consumer Health News Source Type: news
Novel Cannabis Oil Curbs Tics in Severe Tourette's Novel Cannabis Oil Curbs Tics in Severe Tourette's
An oral oil containing THC and CBD reduced tics and psychiatric comorbidity of tics in patients with severe Tourette syndrome in a small clinical trial.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 15, 2023 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Novartis to buy out kidney specialist Chinook Therapeutics in $3.5B deal
Novartis is putting down $3.2 billion in cash to acquire kidney-focused biotech Chinook Therapeutics and its two late-stage drugs for a rare chronic kidney disease. The Swiss pharma giant already has a top drug, iptacopan, that it said showed promise in IgA nephropathy, which…#novartis #kidney #vasnarasimhan #atrasentan #unlock (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2023 Category: Consumer Health News Source Type: news
Ex-Nightstar, Gyroscope and AGTC teams try again for next retinal gene therapy with $120M for Beacon Therapeutics
Life sciences investor Syncona is taking a second shot at X-linked retinitis pigmentosa, this time with Beacon Therapeutics, a retinal gene therapy startup led by former executives of Syncona-backed companies Nightstar Therapeutics and Gyroscope Therapeutics. The…#nightstar #xlrp #biogen #unlock (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2023 Category: Consumer Health News Source Type: news
